ID3
ID3 (DNA-binding protein inhibitor ID-3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Burkitt lymphoma and Diffuse large B-cell lymphoma.
Overview
Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors by forming heterodimers and inhibiting their DNA binding and transcriptional activity. Implicated in regulating a variety of cellular processes, including cellular growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation. Involved in myogenesis by inhibiting skeletal muscle and cardiac myocyte differentiation and promoting muscle precursor cells proliferation.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 5 cohorts (0 activating, 5 loss-of-function), covering Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ID3 (DNA-binding protein inhibitor ID-3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Burkitt lymphoma and Diffuse large B-cell lymphoma.
- 1 · What it is
ID3 (DNA-binding protein inhibitor ID-3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Burkitt lymphoma and Diffuse large B-cell lymphoma.
- 2 · What goes wrong in cancer
Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors by forming heterodimers and inhibiting their DNA binding and transcriptional activity.
- 3 · How drugs use it
No product in this corpus aims at ID3 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:5362 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q02535 (protein name, function text, keywords and locations (REST API)); CIViC gene ID3 (1 evidence items, 0 assertions, 1 variants; diseases: Burkitt Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000117318 (per-cancer scores at or above 0.5: non-Hodgkin lymphoma 0.61, Burkitt lymphoma 0.51 (GraphQL API, CC0)); IntOGen ID3 (driver in 5 cohorts (Act 0, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors by forming heterodimers and inhibiting their DNA binding and transcriptional activity. Implicated in regulating a variety of cellular processes, including cellular growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation. Involved in myogenesis by inhibiting skeletal muscle and cardiac myocyte differentiation and promoting muscle precursor cells proliferation. Inhibits the binding of E2A-containing protein complexes to muscle creatine kinase E-box enhancer. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-BMAL1 heterodimer. Location: Nucleus (UniProt). Locus 1p36.12 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.61 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL)
- Burkitt lymphoma: Open Targets association 0.51 with Burkitt lymphoma (MONDO_0007243); CIViC evidence names this disease
- Diffuse large B-cell lymphoma: IntOGen driver in 1 cohort (DLBCLNOS)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 5 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ID3" OR ABSTRACT:"ID3" OR TITLE:"inhibitor of DNA binding 3" OR ABSTRACT:"inhibitor of DNA binding 3" OR TITLE:"DNA-binding protein inhibitor ID-3" OR ABSTRACT:"DNA-binding protein inhibitor ID-3" OR TITLE:"HEIR-1" OR ABSTRACT:"HEIR-1" OR TITLE:"bHLHb25" OR ABSTRACT:"bHLHb25") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ID3, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetSIN3A
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetP2RY8
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetBCL7A
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetGNA13
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetGNAI2
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), CIViC, IntOGen.
- TargetTFAP4
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), CIViC, IntOGen.
- TargetCCND3
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetFOXO1
Shares Burkitt lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.